Company Team Projects Media Contact

An innovative therapeutic approach to bacterial infection

Combioxin develops innovative anti-virulence treatments for serious bacterial infections, including those caused by antibiotic-resistant strains. The lead candidate, CAL02, is a first-in-class, clinical-stage non-antibiotic liposomal drug that neutralizes bacterial toxins, protects against infection severity and complications, and improves antibiotic efficacy.



Independent Data Monitoring Committee concluded that CAL02 showed positive safety profile at high dose in the CAL02-001 clinical trial in pneumonia patients - 10/10/2017

Combioxin appoints industry veteran Jeffrey Jump as Chairman- 20/07/2017